
Microbot Medical (MBOT) Stock Forecast & Price Target
Microbot Medical (MBOT) Analyst Ratings
Bulls say
Microbot Medical Inc. has recently enhanced its financial position through multiple equity financings and an increase in financing income, which rose to $284K for the quarter compared to $85K in the previous year, underlining improved interest earnings from marketable securities. The company is strategically preparing for its full product launch in the U.S. and Europe, bolstering its commercial capabilities and gathering positive feedback from providers, which positions the LIBERTY Endovascular Robotic System favorably in the market. As a result of these factors, Microbot Medical is expected to experience significant growth momentum and increased operational readiness leading up to key product launches scheduled in the coming years.
Bears say
Microbot Medical faces significant challenges that contribute to a negative outlook on its stock, including delays in the commercialization of its LIBERTY Endovascular Robotic System and potential difficulties in expanding into neuro and cardio markets. Additionally, the company is experiencing a lack of profitability in the near term, compounded by reimbursement headwinds and the erosion of hospital margins due to device costs. The absence of data from randomized controlled trials and the uncertainty surrounding international regulatory approvals further exacerbate the risks related to market adoption and financial performance.
This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.
Microbot Medical (MBOT) Analyst Forecast & Price Prediction
Start investing in Microbot Medical (MBOT)
Order type
Buy in
Order amount
Est. shares
0 shares